I read with interest the article by Murray et al on prevention of
respiratory syncytial virus disease in infants and children. However, the
indications for use of passive immunoprophylaxis with Palivizumab as shown
in Box 1 and referenced to in the statement 'Current JCVI guidance states
that palivizumab is only cost-effective..... at most risk of severe
disease (see box 1)17' are incorrect and represent a mixture of the
indications from the Summary of Product Characteristics and a few of the
JCVI recommendations for those with SCID and long-term ventilation.
The most up to date JCVI guidance for the use of Palivizumab can be found
at
http://webarchive.nationalarchives.gov.uk/20130107105354/https://www.wp.dh.gov.uk/immunisation/files/2012/07/chap
-27a-dh_130131.pdf.
I read with interest the article by Murray et al on prevention of respiratory syncytial virus disease in infants and children. However, the indications for use of passive immunoprophylaxis with Palivizumab as shown in Box 1 and referenced to in the statement 'Current JCVI guidance states that palivizumab is only cost-effective..... at most risk of severe disease (see box 1)17' are incorrect and represent a mixture of the indications from the Summary of Product Characteristics and a few of the JCVI recommendations for those with SCID and long-term ventilation. The most up to date JCVI guidance for the use of Palivizumab can be found at http://webarchive.nationalarchives.gov.uk/20130107105354/https://www.wp.dh.gov.uk/immunisation/files/2012/07/chap -27a-dh_130131.pdf.
Conflict of Interest:
None declared